Literature DB >> 7678351

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

S E Townsend1, J P Allison.   

Abstract

A variety of tumors are potentially immunogenic but do not stimulate an effective anti-tumor immune response in vivo. Tumors may be capable of delivering antigen-specific signals to T cells, but may not deliver the costimulatory signals necessary for full activation of T cells. Expression of the costimulatory ligand B7 on melanoma cells was found to induce the rejection of a murine melanoma in vivo. This rejection was mediated by CD8+ T cells; CD4+ T cells were not required. These results suggest that B7 expression renders tumor cells capable of effective antigen presentation, leading to their eradication in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678351     DOI: 10.1126/science.7678351

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  225 in total

1.  Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.

Authors:  A J Lee; C Haworth; R M Hutchinson; R Patel; R Carter; R F James
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF.

Authors:  A L Gainer; I F Parney; K C Petruk; J F Elliott
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

3.  Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.

Authors:  E D Kwon; A A Hurwitz; B A Foster; C Madias; A L Feldhaus; N M Greenberg; M B Burg; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  B7x: a widely expressed B7 family member that inhibits T cell activation.

Authors:  Xingxing Zang; P'ng Loke; Jayon Kim; Kenneth Murphy; Rebecca Waitz; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-14       Impact factor: 11.205

Review 5.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

Review 6.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

7.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 8.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

9.  Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor.

Authors:  D H Munn; N K Cheung
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

10.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.